Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
Implementing OCREVUS SC at Newcastle
This series of videos features members of the MS MDT (Dr. Martin Duddy, Gillian Kamara, and Gwenda Walker) based at Newcastle Hospitals NHS Foundation Trust discussing their experience of implementing OCREVUS SC at the MS Trust symposium in March 2025 in London.
Watch these clips to learn about the practical steps and teamwork required for implementing this formulation in their service and to gain insights into the impact OCREVUS SC has on patient convenience ( including shorter time in chair and no need for cannulation) and hospital capacity vs OCREVUS IV.
Gillian Kamara, MS Specialist Nurse
Gillian shares the steps taken to implement OCREVUS SC and the importance of preparing and adapting clinical protocols. You will also gain insights into the impact it has had on the service since they started.
Gwenda Walker, Infusion Nurse
Gwenda shares her perspective on her clinical experience treating patients with OCREVUS SC. She also Highlights the impact on patient experience, particularly the reduced treatment time vs OCREVUS IV.
Q&A with Dr Martin Duddy (Consultant Neurologist), Gillian Kamara, & Gwenda Walker
Hear practical questions including patient selection and treatment administration protocols. The discussion gives real-world insights in navigating change & managing patient preferences within a MS service.
If you would like support with training, reach out to a member of our team.
References:
- OCREVUS IV Summary of Product Characteristics
2. OCREVUS SC Summary of Product Characteristics
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.
